KR20220054291A - 개의 만성 신장 질환 치료를 위한 텔미사르탄 - Google Patents

개의 만성 신장 질환 치료를 위한 텔미사르탄 Download PDF

Info

Publication number
KR20220054291A
KR20220054291A KR1020227004466A KR20227004466A KR20220054291A KR 20220054291 A KR20220054291 A KR 20220054291A KR 1020227004466 A KR1020227004466 A KR 1020227004466A KR 20227004466 A KR20227004466 A KR 20227004466A KR 20220054291 A KR20220054291 A KR 20220054291A
Authority
KR
South Korea
Prior art keywords
telmisartan
period
upc
treatment
dog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227004466A
Other languages
English (en)
Korean (ko)
Inventor
앤 미셸 트라스
콜먼 아만다 에릭슨
드 무라 로렌수 비앙카 나탈리아 페레이라
케이트 엘리자베스 크리비
스콧 앨런 브라운
Original Assignee
베링거잉겔하임베트메디카게엠베하
유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거잉겔하임베트메디카게엠베하, 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 filed Critical 베링거잉겔하임베트메디카게엠베하
Publication of KR20220054291A publication Critical patent/KR20220054291A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227004466A 2019-07-09 2020-04-30 개의 만성 신장 질환 치료를 위한 텔미사르탄 Pending KR20220054291A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
US62/871,752 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Publications (1)

Publication Number Publication Date
KR20220054291A true KR20220054291A (ko) 2022-05-02

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004466A Pending KR20220054291A (ko) 2019-07-09 2020-04-30 개의 만성 신장 질환 치료를 위한 텔미사르탄

Country Status (10)

Country Link
US (1) US20220218671A1 (enExample)
EP (1) EP3996705A1 (enExample)
JP (2) JP2022540074A (enExample)
KR (1) KR20220054291A (enExample)
CN (1) CN114450004A (enExample)
AU (1) AU2020311280B2 (enExample)
BR (1) BR112022000315A2 (enExample)
CA (1) CA3142876A1 (enExample)
MX (1) MX2022000429A (enExample)
WO (1) WO2021006941A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats

Also Published As

Publication number Publication date
JP2025120167A (ja) 2025-08-15
BR112022000315A2 (pt) 2022-02-22
TW202116305A (zh) 2021-05-01
US20220218671A1 (en) 2022-07-14
AU2020311280B2 (en) 2026-05-07
MX2022000429A (es) 2022-04-25
WO2021006941A1 (en) 2021-01-14
CN114450004A (zh) 2022-05-06
EP3996705A1 (en) 2022-05-18
AU2020311280A1 (en) 2022-02-24
JP2022540074A (ja) 2022-09-14
CA3142876A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
AU2026202684A1 (en) Telmisartan for the treatment of hypertension in dogs
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
JP2025120167A (ja) イヌの慢性腎臓病の治療のためのテルミサルタン
WO2018143826A1 (en) Cancer therapeutic
TW202541793A (zh) 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑
RU2832966C2 (ru) Телмисартан для лечения хронической болезни почек у собак
RU2830555C2 (ru) Телмисартан для лечения гипертонии у собак
EA026713B1 (ru) Твердая пероральная лекарственная форма для лечения дефицита железа или анемии и ее применение
CN117396197A (zh) 慢性肾脏病的猫的治疗方法
EP4663191A1 (en) Use of tyrosine kinase inhibitor
AU2013203932B2 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CRICLEVIȚ et al. ON THE USE OF TRAZODONE IN VETERINARY MEDICINE

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000